The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (LCC) has a long history of NCTN participation with ECOG membership since 1973. Currently, the LCC infrastructure supports participation in clinical trials and ancillary studies through the ECOG-ACRIN, SWOG, Alliance, NRG and COG. Recognized for accrual, participation and high-level of data quality, the LCC has been selected by the NCTN leadership to participate in the High Performing Site Initiative (HPSI) in 2015, 2016 and 2017 to support our infrastructure and to enable continued participation in NCTN trials. In 2019, Northwestern University was designated as a Lead Academic Performing site (LAPS) and in this new role continues to significantly accrue patients to NCTN trials, exceeding planned accrual goals in both years as a LAPS institution. Through continued demonstration of significant scientific accomplishments and new initiatives, recruitment of accomplished senior faculty and productive junior faculty, comprehensive and integrated infrastructure for oversight of cancer-related clinical trials, LCC will continue to expand participation in NCTN trials, provide scientific leadership of key network activities, and increase inter-institutional collaborations and access to unique scientific resources, to advance cancer interventions.
Home for exceptional science and of internationally renowned cancer experts and supported by a comprehensive clinical research infrastructure, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (LCC) is will continue leadership of and participation in NCTN trials as a high performing LAPS, recruiting patients in the Chicago metropolitan area to trials aiming to improve the lives of people with cancer.
